Alvotech is a global biopharmaceutical company specializing in the development and manufacturing of high-quality biosimilar products. It is part of the privately-owned international pharmaceutical group, Alvin Global Life Science. Alvotech was founded in 2013 and is headquartered in Reykjavik, Iceland. The company's mission is to provide patients worldwide with easier and more affordable access to high-quality, life-changing biopharmaceutical products.
Alvotech's robust pipeline primarily focuses on therapeutic areas such as autoimmunity, dermatology, oncology, ophthalmology, and inflammatory diseases. The company engages in robust, fully integrated in-house capabilities from cell line development to commercial manufacturing. This underscores the company's vertical integration, which is reflective of its commitment to those they provide.
The cornerstone of Alvotech is located in a state-of-the-art biopharmaceutical facility in Reykjavik, where products are developed and manufactured. Furthermore, Alvotech has a strong presence not only in Europe but also in Asia, North, and South America.
Alvotech’s visionary leader, Robert Wessman, has been instrumental in driving its fast-paced growth and establishing strategic partnerships to expand the company's global footprint. Driven by a team of international industry veterans, scientists, and biotech experts, the collective experience and knowledge have led to significant progress and milestones for Alvotech in a short span of time.
Alvotech's commitment to innovation is matched by its dedication to quality. The company operates strictly within the guidelines and regulations prescribed by international health authorities such as the EMA (European Medicines Agency), FDA (Food and Drug Administration), and PMDA (Pharmaceuticals and Medical Devices Agency) in Japan. These robust quality controls combine with their rigorous development process to ensure the safety and efficacy of all their products.
Alvotech prides itself on its steadfast commitment to improve patient accessibility to biological therapies. By providing high-quality, similar biological medicinal products at competitive prices, Alvotech has positioned itself as a key player in the global biosimilar market. Guided by a vision of transforming the lives of patients worldwide, Alvotech continues to drive change within the biopharmaceutical industry through innovation, quality, and a patient-centered approach.
This commitment to excellence and patient care has positioned Alvotech as an emerging leader in the biosimilars industry. With its integrated capabilities, expansive biosimilar pipeline, and global distribution network, Alvotech is well positioned to make a significant impact on global healthcare. Through its endeavour, Alvotech emphasises the importance of enabling access to advanced biological medication, confirming its place as a forward-thinking key player in the biopharmaceutical sector.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Alvotech (NASDAQ: ALVO) reported a third-quarter loss of $0.03 per share on revenue of $111.56 million, missing analyst estimates. While product and service revenue saw a significant year-over-year increase, licensing and other revenue declined, offsetting much of the gain. The company reaffirmed its full-year 2026 revenue and EBITDA guidance but now expects to land at the lower end of those ranges, placing significant reliance on a record-breaking fourth quarter.
Alvotech announced its financial results for the nine months ended September 30, 2026, reporting adjusted total revenue of $323.4 million and adjusted EBITDA of $78.3 million. The company also provided a business update highlighting recent FDA approvals for Simlandi®, pipeline advancements including submissions for biosimilars to Entyvio® and Eylea HD, and new commercial partnerships. Alvotech maintained its full-year 2026 guidance for total revenue and EBITDA, expecting performance towards the lower end of the range.
Alvotech (NASDAQ:ALVO) shares have fallen significantly over the past five years, leading investors to question if the current valuation aligns with its sales base. The company's P/S ratio of 3.5x is below the biotech industry average, suggesting it may be undervalued. While some investors see potential in its biosimilar pipeline, others are concerned about thin margins and funding pressures.
Alvotech (NASDAQ:ALVO) has been downgraded from a "hold" to a "sell" rating by Wall Street Zen. Despite this, other analysts have mixed views, with four "Buy" ratings and two "Sell" ratings, resulting in an average "Hold" and a consensus price target of $8.25. The company recently reported an EPS loss of $0.11, missing estimates, but exceeded revenue expectations with $106 million.